
MEK INHIBITORS IN NEUROFIBROMATOSIS TYPE 1

Latest Advances and Real-world Applications in NF1-PN Management



Held in conjunction with the 2025 ASPHO Conference

Thursday, May 8, 2025

12:00 PM Doors open


12:15–1:15 PM ET Presentation

Kentucky International Convention Center
Ballroom B

cec ONCOLOGY

Latest Advances and Real-world Applications in NF1-PN Management

MEK INHIBITORS IN NEUROFIBROMATOSIS TYPE 1



Activity Description

In this CEC Oncology live, case-based symposium, expert faculty will discuss diagnosis and disease challenges over a person's lifespan; explore the integration of MEK inhibitors in the management of NF1-associated PNs in pediatric patients; and consider comprehensive interprofessional care plans that include disease monitoring, toxicity management, and individualizing disease treatment across the patient's lifespan.

Target Audience

Neuro-oncologists, general oncologists, general neurologists, pediatric oncologists, physician associates (PAs), nurse practitioners (NPs), and nurses

Financial Support

This program is supported through independent educational grants from Alexion Pharmaceuticals and SpringWorks Therapeutics, Inc.

Faculty

Angela Hirbe
MD, PhD

Amy Armstrong
MD

Learning Objectives


At the conclusion of this activity, learners will be able to better:

- Identify key characteristics of neurofibromatosis type 1 (NF1) clinical presentation and disease advancement across the lifespan, including genetic etiology and multisystem pathophysiology of NF1, that impact early and accurate diagnosis
- Integrate MEK inhibitors in the management of NF1-associated plexiform neurofibromas (PNs) in pediatric patients
- Develop comprehensive care plans that include disease monitoring, managing toxicities, and personalized treatment for patients with NF1 across the lifespan

© 2025 CE CONCEPTS. ALL RIGHTS RESERVED.

Latest Advances and Real-world Applications in NF1-PN Management

MEK INHIBITORS IN NEUROFIBROMATOSIS TYPE 1



Accreditation

Jointly Accredited Provider

In support of improving patient care, Creative Educational Concepts, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

IPCE

This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education Credit for learning and change.

Physicians (ACCME)

Creative Educational Concepts, LLC, designates this live activity for a maximum of 1.0 *AMA PRA Category 1 Credit(s)*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses (ANCC)

This activity is designated for 1.0 contact hours.

Pharmacotherapy: ANCC definition of pharmacotherapeutic content is that it may include but is not limited to drug-specific information, safe prescribing practices, safe medication administration, prescribing methodologies, new regulations, or similar content.

Note to Nurse Practitioners: The content of this CNE activity pertains to Pharmacology.

Oncology Nursing Certification (ONCC) [ILNA]

This activity is designated for 1.0 contact hours. The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points.

RCP Canada

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.

Certificate of Participation

This activity was certified for a maximum of 1.0 *AMA PRA Category 1 Credit(s)*™.

MIPS

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.


ABIM MOC

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

© 2025 CE CONCEPTS. ALL RIGHTS RESERVED.

Latest Advances and Real-world Applications in NF1-PN Management

MEK INHIBITORS IN NEUROFIBROMATOSIS TYPE 1



Faculty



Angela Hirbe
MD, PhD

Associate Professor of Medicine and Pediatrics
Director, Adult Neurofibromatosis Clinical Program
Division of Oncology, Sarcoma Section
Washington University School of Medicine
St. Louis, Missouri

Angela Hirbe, MD, PhD, is a practicing medical oncologist who treats sarcoma. Her research focuses on utilization of genomic information from sarcomas to better understand the pathogenesis of these tumors and to identify biomarkers and therapeutic targets for these aggressive cancers.



Amy Armstrong
MD


Associate Professor of Pediatrics
Director, Solid Tumor Program
Co-Director, Adolescent and Young Adult Sarcoma Program
Washington University School of Medicine
St. Louis Children's Hospital
Division of Pediatric Hematology/Oncology
St. Louis, Missouri

Amy Armstrong, MD, is a pediatric oncologist who directs the Solid Tumor Program at Siteman Kids, affiliated with St. Louis Children's Hospital, as well as co-directs the Adolescent and Young Adult Sarcoma Program in collaboration with Siteman Kids and Siteman Cancer Center. She is an associate professor of pediatrics at Washington University–St. Louis and has research interests in Neurofibromatosis Type 1 (NF1)–related plexiform neurofibromas (PNs), renal tumors, and sarcomas found most in the adolescent and young adult population. Dr. Armstrong serves as site Principal Investigator for the Children's Oncology Group, Neurofibromatosis Clinical Trials Consortium, and National Pediatric Cancer Foundation, and is invested in conducting and developing clinical trials to serve a diverse range of solid tumors in both the upfront and relapsed setting.

© 2025 CE CONCEPTS. ALL RIGHTS RESERVED.

Latest Advances and Real-world Applications in NF1-PN Management

MEK INHIBITORS IN NEUROFIBROMATOSIS TYPE 1



Disclosure Declarations

It is the policy of Creative Educational Concepts, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. Creative Educational Concepts, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Faculty

Dr. Hirbe reports the following financial relationships:

Advisory Board: Aadi Subsidiary, Inc.

Consultant: Aadi Subsidiary, Inc.; Alexion Pharmaceuticals, Inc.; AstraZeneca; and SpringWorks Therapeutics, Inc.

Grants: Tango

Other financial or material support: Boehringer Ingelheim

Dr. Armstrong reports the following financial relationships:

Advisory Board: Alexion Pharmaceuticals, Inc

Consultant: Alexion Pharmaceuticals, Inc. and SpringWorks Therapeutics, Inc.

Peer Reviewers

Alaa Bawaneh, MD, PhD—no disclosures to report.

Andrea Edwards, PA-C—no disclosures to report.

Patient Advocate/Planner

Evan Neale—no disclosures to report.

Sarah Neale—no disclosures to report.

CEC Staff/Planners

David Modrak, PhD—no disclosures to report.

Nichole Lainhart—no disclosures to report.

Scott J. Hershman, MD, FACEHP, CHCP—no disclosures to report.

Sandra Caballero, PharmD—no disclosures to report.

Sharon Tordoff—no disclosures to report.

**All identified conflicts of interest have been mitigated.*


Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac.

© 2025 CE CONCEPTS. ALL RIGHTS RESERVED.

Latest Advances and Real-world Applications in NF1-PN Management

MEK INHIBITORS IN NEUROFIBROMATOSIS TYPE 1



Instructions for Interactive Technology

Use one of the iPads provided at your table to answer polling questions, view onsite presentations, and submit questions to the faculty.

Ask Faculty a Question

Select the Ask Question tab below the slide viewer to submit a question. If your question is for a specific faculty member, please include their name. Your question will be shared with the faculty for the question-and-answer portion of the session.

View and Take Notes on Presentation Slides

Select the Take Notes tab to take notes during the meeting. All of the notes you take during the meeting will be emailed to the address provided within 5 business days.

Obtaining Credit

To receive CME/CE credit for this activity, scan the QR code to log in to or to create a learner account.

Downloadable Resources

Downloadable resources will be available at **ceconcepts.com/NF1PNresources**.

Engage with Us

Follow us **@ceconcepts** for announcements about upcoming CME opportunities, health care news, and more!

Thank you for joining us today!

cec ONCOLOGY

© 2025 CE CONCEPTS. ALL RIGHTS RESERVED.